Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 1 (2004), Issue 2 (November)

1. Active transport of imatinib into and out of cells: implications for drug resistance.
   Blood, 104(12): 3739-45. [Abstract] [Full-text]
2. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia.
   Blood, 104(12): 3507-12. [Abstract] [Full-text]
3. Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970.
   Blood, 104(12): 3754-7. [Abstract] [Full-text]
4. Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo.
   Leukemia, 18(12): 1951-63. [Abstract] [Full-text]
5. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
   Cancer, 101(11): 2574-83. [Abstract] [Full-text]
6. Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
   Cancer, 101(11): 2584-92. [Abstract] [Full-text]
7. Inhibition of HMC-1 mast cell proliferation by vitamin E: involvement of the protein kinase B pathway.
   J Biol Chem, 279(49): 50700-9. [Abstract] [Full-text]
8. Imatinib mesylate induces apoptosis in human cholangiocarcinoma cells.
   Liver Int, 24(6): 687-95. [Abstract] [Full-text]
9. Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t(15;19): case report.
   Am J Hematol, 77(4): 366-9. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.